1 es was significantly higher in patients with
non-alcoholic fatty liver.
2 severity of liver steatosis in subjects with
non-alcoholic fatty liver.
3 markers of oxidative stress in subjects with
non-alcoholic fatty liver.
4 tors to diseases like obesity, diabetes, and
non-alcoholic fatty liver.
5 may be a cryptic co-factor in some cases of
non-alcoholic fatty liver.
6 der-Willi syndrome - and reduced HFD-induced
non-alcoholic fatty liver.
7 mmation and faster fibrosis progression than
non-alcoholic fatty liver.
8 iso-PGF2alpha were independent predictors of
non-alcoholic fatty liver and a strong association of ur
9 of oxidative stress markers in patients with
non-alcoholic fatty liver and no study has been performe
10 ar disease, type 2 diabetes, atherosclerosis,
non-alcoholic fatty liver,
and cancer.
11 tokine fetuin-A may impair renal function in
non alcoholic fatty liver disease (NAFLD) by altering in
12 = 2.4 x 10 -5 ), liver cancer ( p = 0.007),
non-alcoholic fatty liver disease ( p = 7.7 x 10 -11 ),
13 cirrhosis (14.5%), hepatitis C (13.4%), and
non-alcoholic fatty liver disease (5.7%).
14 Participants with
non-alcoholic fatty liver disease (defined as (1)H magne
15 7, 95% CI: 2.51-33.50, p = 3.8 x 10 -7 ) and
Non-alcoholic fatty liver disease (hazard ratio = 5.17,
16 HSCs and in a human cohort of subjects with
non-alcoholic fatty liver disease (N = 146).
17 s with adipose tissue insulin resistance and
non-alcoholic fatty liver disease (n = 210, Germany).
18 sis models (n = 3-5) and in human samples of
non-alcoholic fatty liver disease (NAFLD) (n = 72-135).
19 iatal hernia (HH) (OR 4.07 [3.21-5.17]), and
non-alcoholic fatty liver disease (NAFLD) (OR 1.26 [1.18
20 ed study, adult patients with definite NASH,
non-alcoholic fatty liver disease (NAFLD) activity score
21 Non-alcoholic fatty liver disease (NAFLD) affects 1 in 3
22 Non-alcoholic fatty liver disease (NAFLD) affects 20-30%
23 Non-alcoholic fatty liver disease (NAFLD) affects 25% of
24 Non-alcoholic fatty liver disease (NAFLD) affects a larg
25 Non-alcoholic fatty liver disease (NAFLD) affects about
26 Non-alcoholic fatty liver disease (NAFLD) affects nearly
27 Non-alcoholic fatty liver disease (NAFLD) affects over 3
28 The prevalence and outcomes of
non-alcoholic fatty liver disease (NAFLD) among elderly
29 e and altered energy metabolism is common in
non-alcoholic fatty liver disease (NAFLD) and appears to
30 Non-alcoholic fatty liver disease (NAFLD) and cardiovasc
31 n of Sonic Hedgehog (SHH) is associated with
Non-alcoholic fatty liver disease (NAFLD) and developmen
32 of carbohydrates, fat and calories leads to
non-alcoholic fatty liver disease (NAFLD) and hepatic in
33 the gut microbiota in choline deficiency in
non-alcoholic fatty liver disease (NAFLD) and insulin re
34 ed thermogenesis, promoting greater obesity,
non-alcoholic fatty liver disease (NAFLD) and insulin re
35 Obesity,
non-alcoholic fatty liver disease (NAFLD) and insulin re
36 Non-alcoholic fatty liver disease (NAFLD) and its more s
37 e similar to those observed in patients with
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoho
38 Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoho
39 o examine the associations of adiposity with
non-alcoholic fatty liver disease (NAFLD) and other chro
40 patitis (NASH) is an inflammatory subtype of
non-alcoholic fatty liver disease (NAFLD) and recent non
41 olic syndrome, obesity, type II diabetes and
non-alcoholic fatty liver disease (NAFLD) are increasing
42 disease especially in diabetes mellitus and
non-alcoholic fatty liver disease (NAFLD) but studies ex
43 Increasing incidence of
non-alcoholic fatty liver disease (NAFLD) calls for impr
44 he serum XPO4 pattern in a broad spectrum of
non-alcoholic fatty liver disease (NAFLD) cases.
45 Non-alcoholic fatty liver disease (NAFLD) characterizes
46 citing greater weight loss and reductions in
non-alcoholic fatty liver disease (NAFLD) compared to ca
47 Non-alcoholic fatty liver disease (NAFLD) comprises a ra
48 Non-alcoholic fatty liver disease (NAFLD) constitutes a
49 afer and more effective hepatitis C therapy,
non-alcoholic fatty liver disease (NAFLD) could soon eme
50 The approach was developed on a
non-alcoholic fatty liver disease (NAFLD) data set.
51 e a non-invasive fibrosis scoring system for
non-alcoholic fatty liver disease (NAFLD) derived from r
52 Although the progression of
non-alcoholic fatty liver disease (NAFLD) from steatosis
53 Non-alcoholic fatty liver disease (NAFLD) has a global p
54 Non-alcoholic fatty liver disease (NAFLD) has become the
55 Non-alcoholic fatty liver disease (NAFLD) has become the
56 Non-alcoholic fatty liver disease (NAFLD) has been recen
57 Non-alcoholic fatty liver disease (NAFLD) has emerged as
58 on liver function in bariatric patients with
non-alcoholic fatty liver disease (NAFLD) in a randomize
59 Recent studies have raised the concept that
non-alcoholic fatty liver disease (NAFLD) in adults is d
60 and lipogenesis are also central features of
non-alcoholic fatty liver disease (NAFLD) in both rodent
61 elicits pathologies in rodents that resemble
non-alcoholic fatty liver disease (NAFLD) in humans thro
62 Non-alcoholic fatty liver disease (NAFLD) in lean patien
63 Considering the high prevalence of
non-alcoholic fatty liver disease (NAFLD) in patients wi
64 Mitochondrial adaptation during
non-alcoholic fatty liver disease (NAFLD) include remode
65 The incidence of
non-alcoholic fatty liver disease (NAFLD) increases with
66 Almost all effective treatments for
non-alcoholic fatty liver disease (NAFLD) involve reduct
67 Non-alcoholic fatty liver disease (NAFLD) is a common ch
68 Non-alcoholic fatty liver disease (NAFLD) is a common di
69 Non-alcoholic fatty liver disease (NAFLD) is a common me
70 Non-alcoholic fatty liver disease (NAFLD) is a complex c
71 Non-alcoholic fatty liver disease (NAFLD) is a frequent
72 Non-alcoholic fatty liver disease (NAFLD) is a global pr
73 Non-alcoholic fatty liver disease (NAFLD) is a growing e
74 Non-alcoholic fatty liver disease (NAFLD) is a highly pr
75 Non-alcoholic fatty liver disease (NAFLD) is a leading c
76 Non-alcoholic fatty liver disease (NAFLD) is a major ris
77 Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressi
78 Non-alcoholic fatty liver disease (NAFLD) is a rising gl
79 Non-alcoholic fatty liver disease (NAFLD) is a substanti
80 Non-alcoholic fatty liver disease (NAFLD) is an emerging
81 Non-alcoholic fatty liver disease (NAFLD) is an increasi
82 y in people living with HIV (PLWH), of which
non-alcoholic fatty liver disease (NAFLD) is an increasi
83 Non-alcoholic fatty liver disease (NAFLD) is an obesity-
84 Non-alcoholic fatty liver disease (NAFLD) is associated
85 Non-alcoholic fatty liver disease (NAFLD) is associated
86 Non-alcoholic fatty liver disease (NAFLD) is becoming th
87 Non-alcoholic fatty liver disease (NAFLD) is characteriz
88 Non-alcoholic fatty liver disease (NAFLD) is characteriz
89 Non-alcoholic fatty liver disease (NAFLD) is defined as
90 of the gut microbiome in the pathogenesis of
non-alcoholic fatty liver disease (NAFLD) is emerging.
91 Non-alcoholic fatty liver disease (NAFLD) is highly prev
92 The worldwide prevalence of
non-alcoholic fatty liver disease (NAFLD) is increasing
93 The prevalence of
non-alcoholic fatty liver disease (NAFLD) is increasing
94 but the role of stress in the development of
non-alcoholic fatty liver disease (NAFLD) is largely une
95 Non-alcoholic fatty liver disease (NAFLD) is often assoc
96 Non-alcoholic fatty liver disease (NAFLD) is one of the
97 Non-alcoholic fatty liver disease (NAFLD) is one of the
98 Non-alcoholic fatty liver disease (NAFLD) is one of the
99 Non-alcoholic fatty liver disease (NAFLD) is one of the
100 The prevailing theory in
non-alcoholic fatty liver disease (NAFLD) is the "two-hi
101 Non-alcoholic fatty liver disease (NAFLD) is the commone
102 Non-alcoholic fatty liver disease (NAFLD) is the hepatic
103 Non-alcoholic fatty liver disease (NAFLD) is the most co
104 Non-alcoholic fatty liver disease (NAFLD) is the most co
105 Non-alcoholic fatty liver disease (NAFLD) is the most co
106 Non-alcoholic fatty liver disease (NAFLD) is the most co
107 Non-alcoholic fatty liver disease (NAFLD) is the most co
108 Non-alcoholic fatty liver disease (NAFLD) is the most co
109 Non-alcoholic fatty liver disease (NAFLD) is the most co
110 Non-alcoholic fatty liver disease (NAFLD) is the most co
111 Non-alcoholic fatty liver disease (NAFLD) is the most co
112 Non-alcoholic fatty liver disease (NAFLD) is the most pr
113 However, its impact on
non-alcoholic fatty liver disease (NAFLD) is unknown.
114 Non-alcoholic fatty liver disease (NAFLD) is widespread
115 CC, common causes of liver inflammation like
non-alcoholic fatty liver disease (NAFLD) may increase t
116 ltered cellular lipid storage on obesity and
non-alcoholic fatty liver disease (NAFLD) pathophysiolog
117 In
non-alcoholic fatty liver disease (NAFLD) patients and o
118 s with sustained virological response and 93
non-alcoholic fatty liver disease (NAFLD) patients were
119 ociated genes in the gastric tissue of obese
non-alcoholic fatty liver disease (NAFLD) patients.
120 ts with advanced liver fibrosis secondary to
non-alcoholic fatty liver disease (NAFLD) remains challe
121 Non-alcoholic fatty liver disease (NAFLD) represents a s
122 The process initiates with
non-alcoholic fatty liver disease (NAFLD) that progresse
123 Increasing evidence connects
non-alcoholic fatty liver disease (NAFLD) to CKD.
124 tors FXR and CAR in disease progression from
non-alcoholic fatty liver disease (NAFLD) to HCC.
125 or contributors to the growing prevalence of
non-alcoholic fatty liver disease (NAFLD), a chronic liv
126 atohepatitis (NASH) is a progressive form of
Non-alcoholic fatty liver disease (NAFLD), a chronic liv
127 There is no licensed treatment for
non-alcoholic fatty liver disease (NAFLD), a condition t
128 -2006), overweight children with and without
non-alcoholic fatty liver disease (NAFLD), and children
129 t only affected by the metabolic syndrome as
non-alcoholic fatty liver disease (NAFLD), but may contr
130 yndrome (PCOS) is frequently associated with
non-alcoholic fatty liver disease (NAFLD), but the mecha
131 ynthesis are critical for the progression of
non-alcoholic fatty liver disease (NAFLD), but the under
132 d autophagy is associated with steatosis and
non-alcoholic fatty liver disease (NAFLD), however the m
133 In
non-alcoholic fatty liver disease (NAFLD), lipid build-u
134 SF3 is decreased in human liver samples with
non-alcoholic fatty liver disease (NAFLD), non-alcoholic
135 (TMC4) that associate with increased risk of
non-alcoholic fatty liver disease (NAFLD), non-alcoholic
136 blood spot testing-is often misdiagnosed as
non-alcoholic fatty liver disease (NAFLD), non-alcoholic
137 Non-alcoholic fatty liver disease (NAFLD), recently recl
138 with chronic hepatitis B (CHB) and 488 with
non-alcoholic fatty liver disease (NAFLD), those with rs
139 hronic metabolic diseases including obesity,
non-alcoholic fatty liver disease (NAFLD), type 2 diabet
140 biting recessive male-specific lethality and
non-alcoholic fatty liver disease (NAFLD), which coincid
141 Non-alcoholic fatty liver disease (NAFLD), which include
142 Obesity triggers the development of
non-alcoholic fatty liver disease (NAFLD), which involve
143 Non-alcoholic fatty liver disease (NAFLD), which is clos
144 s a high-prevalence, rapidly growing form of
non-alcoholic fatty liver disease (NAFLD), which is clos
145 chanisms differ in drug induced (DIS) and/or
non-alcoholic fatty liver disease (NAFLD).
146 d increased oxidative damage are features of
non-alcoholic fatty liver disease (NAFLD).
147 ged as a potential plasma marker to diagnose
non-alcoholic fatty liver disease (NAFLD).
148 e (BBR) is beneficial for obesity-associated
non-alcoholic fatty liver disease (NAFLD).
149 efficacy of sevelamer in treating mice with
non-alcoholic fatty liver disease (NAFLD).
150 Visceral obesity is often accompanied by
non-alcoholic fatty liver disease (NAFLD).
151 umulation, a characteristic of patients with
non-alcoholic fatty liver disease (NAFLD).
152 otein (HP)-diet and/or beta-cryptoxanthin in
non-alcoholic fatty liver disease (NAFLD).
153 lism might contribute to the pathogenesis of
non-alcoholic fatty liver disease (NAFLD).
154 s that parallel stages in the development of
non-alcoholic fatty liver disease (NAFLD).
155 sociated with the development of obesity and
non-alcoholic fatty liver disease (NAFLD).
156 corticoids contribute to the pathogenesis of
non-alcoholic fatty liver disease (NAFLD).
157 RNA processing, are significantly altered in
non-alcoholic fatty liver disease (NAFLD).
158 liver related complications in patients with
non-alcoholic fatty liver disease (NAFLD).
159 el human pathologies, including fibrosis and
non-alcoholic fatty liver disease (NAFLD).
160 atohepatitis (NASH), the progressive form of
non-alcoholic fatty liver disease (NAFLD).
161 h is particularly relevant in the context of
non-alcoholic fatty liver disease (NAFLD).
162 in the circadian clock desynchrony-mediated
Non-alcoholic fatty liver disease (NAFLD).
163 story of liver disease or varying degrees of
non-alcoholic fatty liver disease (NAFLD).
164 n the prevention or delaying of the onset of
non-alcoholic fatty liver disease (NAFLD).
165 are common problems among participants with
non-alcoholic fatty liver disease (NAFLD).
166 hildren has been linked to increased risk of
non-alcoholic fatty liver disease (NAFLD).
167 onfers protection against the development of
non-alcoholic fatty liver disease (NAFLD).
168 adverse health outcomes in humans including
non-alcoholic fatty liver disease (NAFLD).
169 patic 12-hour clock and promotes spontaneous
non-alcoholic fatty liver disease (NAFLD).
170 dices, and hepatic features in patients with
non-alcoholic fatty liver disease (NAFLD).
171 caemic control in pre-diabetic patients with
non-alcoholic fatty liver disease (NAFLD).
172 iated with metabolic abnormalities including
non-alcoholic fatty liver disease (NAFLD).
173 d increased oxidative damage are features of
non-alcoholic fatty liver disease (NAFLD).
174 protein F (APO-F), a potential biomarker for
non-alcoholic fatty liver disease (NAFLD).
175 c steatosis both in an inbred mouse model of
non-alcoholic fatty liver disease (SJL/J) and in a human
176 red liver histology defined as a decrease in
non-alcoholic fatty liver disease activity score by at l
177 ears) with biopsy-confirmed MASH (defined as
non-alcoholic fatty liver disease activity score of 4 or
178 ntent), as well as elevated inflammation and
non-alcoholic fatty liver disease activity scores, and h
179 In 2021, the estimated global cases of
non-alcoholic fatty liver disease among adolescents and
180 inflammation and fibrosis in mouse models of
non-alcoholic fatty liver disease and advanced fibrosis,
181 rently, the main etiologies of cirrhosis are
non-alcoholic fatty liver disease and alcohol-related li
182 , diabetes mellitus, chronic kidney disease,
non-alcoholic fatty liver disease and autoimmune and neu
183 in both the metabolic syndrome accompanying
non-alcoholic fatty liver disease and cellular apoptosis
184 Increases in
non-alcoholic fatty liver disease and drug-induced hepat
185 Non-alcoholic fatty liver disease and early fibrosis wer
186 t loss is an effective strategy for treating
non-alcoholic fatty liver disease and improving insulin
187 Non-alcoholic fatty liver disease and its downstream seq
188 wed a substantial overlap with biomarkers of
non-alcoholic fatty liver disease and its progression to
189 ACT: Low aerobic capacity increases risk for
non-alcoholic fatty liver disease and liver-related dise
190 plasma lipoprotein metabolism, alcoholic and
non-alcoholic fatty liver disease and myocardial infarct
191 ht to be of relevance for the development of
non-alcoholic fatty liver disease and obesity.
192 ute to various metabolic diseases, including
non-alcoholic fatty liver disease and type 2 diabetes.
193 ism could alleviate the related epidemics of
non-alcoholic fatty liver disease and type 2 diabetes.
194 y for treating inflammatory diseases such as
non-alcoholic fatty liver disease and type 2 diabetes.
195 % males), mean age 47.6 years, predominantly
non-alcoholic fatty liver disease and viral hepatitis (6
196 Ninety four eligible patients who have
non-alcoholic fatty liver disease and who are insulin re
197 complications such as insulin resistance and
non-alcoholic fatty liver disease are reaching epidemic
198 entify predictors of fibrosis progression in
non-alcoholic fatty liver disease as a case study.
199 , GLUT2 may contribute to the development of
non-alcoholic fatty liver disease by facilitating the up
200 ysregulation of the liver metabolism such as
non-alcoholic fatty liver disease confer an increased ri
201 All patients had normal Fibrosis-4 Index and
Non-alcoholic fatty liver disease fibrosis biomarker sco
202 sity and obesity are common in cirrhosis and
non-alcoholic fatty liver disease has become an importan
203 ein 5 in vivo prior to or after establishing
non-alcoholic fatty liver disease in mice.
204 ivity, and prevents metabolic stress-induced
non-alcoholic fatty liver disease in mice.
205 tic fat accumulation and provides a model of
non-alcoholic fatty liver disease in which to study the
206 Non-alcoholic fatty liver disease is a continuum of diso
207 Non-alcoholic fatty liver disease is a serious health pr
208 mmation and fibrosis in humans and mice with
non-alcoholic fatty liver disease is accompanied by accu
209 Non-alcoholic fatty liver disease is associated with hep
210 Non-alcoholic fatty liver disease is associated with mul
211 Steatohepatitis due to
non-alcoholic fatty liver disease is developing into a n
212 Monitoring the progression of
non-alcoholic fatty liver disease is hindered by a lack
213 The prevalence of
non-alcoholic fatty liver disease is increasing worldwid
214 Non-alcoholic fatty liver disease is one of the most com
215 s and alcohol remain important risk factors,
non-alcoholic fatty liver disease is rapidly becoming a
216 Non-alcoholic fatty liver disease is the most rapidly gr
217 The progressive
non-alcoholic fatty liver disease observed in the LCR ra
218 Remarkably, in
non-alcoholic fatty liver disease patients, hepatic expr
219 Non-alcoholic fatty liver disease ranges from steatosis
220 le-nucleotide variants in the progression of
non-alcoholic fatty liver disease to non-alcoholic steat
221 Non-alcoholic fatty liver disease was confirmed in all m
222 ntributed to increasing rates of obesity and
non-alcoholic fatty liver disease(2-4).
223 patients with histologically-defined NAFLD (
non-alcoholic fatty liver disease) activity score (NAS)
224 ic liver disease (MASLD; previously known as
non-alcoholic fatty liver disease) is the leading cause
225 hospholipase domain-containing protein 3 and
non-alcoholic fatty liver disease, a previously reported
226 betes mellitus, insulin resistance (IR), and
non-alcoholic fatty liver disease, although its role in
227 besity, insulin resistance, type 2 diabetes,
non-alcoholic fatty liver disease, and cancer.
228 des a novel mechanistic link between T2D and
non-alcoholic fatty liver disease, and demonstrate in vi
229 bowel syndrome, and metabolic (i.e. obesity,
non-alcoholic fatty liver disease, and diabetes) and neu
230 mote progression of alcoholic liver disease,
non-alcoholic fatty liver disease, and non-alcoholic ste
231 en in both alcohol-related liver disease and
non-alcoholic fatty liver disease, but rarely in hepatoc
232 ns or rodents to high-calorie diets promotes
non-alcoholic fatty liver disease, characterized by neut
233 Non-alcoholic fatty liver disease, characterized in part
234 sis of several metabolic diseases, including
non-alcoholic fatty liver disease, diabetes mellitus, an
235 with risk factors of liver disease, such as
non-alcoholic fatty liver disease, hazardous alcohol use
236 quence of different causes, such as obesity,
non-alcoholic fatty liver disease, high alcohol consumpt
237 at diet (HFD) consumption is associated with
non-alcoholic fatty liver disease, increased apoptosis,
238 onic liver injury mouse model recapitulating
non-alcoholic fatty liver disease, injections of both HG
239 y Liver Disease (MAFLD), previously known as
Non-Alcoholic Fatty Liver Disease, is a growing global h
240 Given the increasing prevalence of
non-alcoholic fatty liver disease, it is necessary to fi
241 y and progression of liver diseases, such as
non-alcoholic fatty liver disease, non-alcoholic steatoh
242 was also able to reverse already established
non-alcoholic fatty liver disease, resulting in signific
243 Applied to
non-alcoholic fatty liver disease, SCCAF-D unveils meani
244 Non-alcoholic fatty liver disease, the most prevalent li
245 In a diet-induced mouse model of
non-alcoholic fatty liver disease, the sensor achieved o
246 In a diet-induced mouse model of
non-alcoholic fatty liver disease, the sensor achieved o
247 dge about TM6SF2 and PNPLA3 polymorphisms in
non-alcoholic fatty liver disease, their influence in th
248 factors contributing to the pathogenesis of
non-alcoholic fatty liver disease, we examined liver ste
249 type 2 diabetes mellitus has been linked to
non-alcoholic fatty liver disease, which can progress to
250 These findings may also apply to
non-alcoholic fatty liver disease, which shares similar
251 e excess alcohol intake, viral hepatitis and
non-alcoholic fatty liver disease, with the clinical spe
252 ent or progression of alcohol-associated and
non-alcoholic fatty liver disease-the most common chroni
253 complications of metabolic syndrome, such as
non-alcoholic fatty liver disease.
254 BP-regulated de novo lipogenesis involved in
non-alcoholic fatty liver disease.
255 provide unique targets for the treatment of
non-alcoholic fatty liver disease.
256 lly therapeutic role of PHLPP2 activators in
non-alcoholic fatty liver disease.
257 and metabolic outcomes in participants with
non-alcoholic fatty liver disease.
258 have liver fibrosis, mostly associated with
non-alcoholic fatty liver disease.
259 tal steatosis, a hallmark of human pediatric
non-alcoholic fatty liver disease.
260 n that causes insulin-resistant diabetes and
non-alcoholic fatty liver disease.
261 be a promising approach for the treatment of
non-alcoholic fatty liver disease.
262 type 2 diabetes, cardiovascular disease, and
non-alcoholic fatty liver disease.
263 etes, atherosclerotic vascular diseases, and
non-alcoholic fatty liver disease.
264 nisms responsible for disease progression in
non-alcoholic fatty liver disease.
265 erglycaemic, hyperinsulinaemic and developed
non-alcoholic fatty liver disease.
266 ovel therapeutic target for diseases such as
non-alcoholic fatty liver disease.
267 potential to treat both atherosclerosis and
non-alcoholic fatty liver disease.
268 present a novel avenue for the treatment of
non-alcoholic fatty liver disease.
269 ch probably increasing the susceptibility to
non-alcoholic fatty liver disease.
270 and concomitant protection from diet-induced
non-alcoholic fatty liver disease.
271 and hepatocyte lipoapoptosis are features of
non-alcoholic fatty liver disease.
272 ses, including type 1 diabetes, obesity, and
non-alcoholic fatty liver disease.
273 insulin resistance and an increased risk of
non-alcoholic fatty liver disease.
274 associated with obesity, type 2 diabetes and
non-alcoholic fatty liver disease.
275 controls, alcohol-related liver disease and
non-alcoholic fatty liver disease.
276 enzyme that is upregulated in patients with
non-alcoholic fatty liver disease.
277 , metabolic syndrome, diabetes mellitus, and
non-alcoholic fatty liver disease.
278 gent somatic mutation in alcohol-related and
non-alcoholic fatty liver disease.
279 eral diseases, including type 2 diabetes and
non-alcoholic fatty liver disease.
280 eneficial effects that have implications for
non-alcoholic fatty liver disease.
281 lin resistance, type 2 diabetes mellitus and
non-alcoholic fatty liver disease.
282 to mitigate the complications of obesity and
non-alcoholic fatty liver disease.
283 function in other hepatic diseases, such as
non-alcoholic fatty liver disease.
284 eatures of the metabolic syndrome, including
non-alcoholic fatty liver disease.
285 ecies (ROS) contribute to the development of
non-alcoholic fatty liver disease.
286 tabolic diseases such as type 2 diabetes and
non-alcoholic fatty liver disease.
287 hepatitis C and emergence of cirrhosis from
non-alcoholic fatty liver disease.
288 f metabolic conditions including obesity and
non-alcoholic fatty liver disease.
289 ased atherosclerosis, increased obesity, and
non-alcoholic fatty liver disease.
290 ages might be a novel therapeutic target for
non-alcoholic fatty liver disease.
291 t CaMKK2 function confers protection against
non-alcoholic fatty liver disease.
292 been implicated in fatty liver formation in
non-alcoholic fatty liver disease.
293 ity, adipocyte hypertrophy, and present with
non-alcoholic fatty liver disease; 3) DKO mice demonstra
294 Non-alcoholic fatty-liver disease (NAFLD) is frequent in
295 Patients with
non-alcoholic fatty liver had higher (p < 0.001) mean va
296 Non-alcoholic fatty liver is the most common liver disea
297 Non-alcoholic fatty liver (
NAFL) and related syndromes a
298 rdiovascular (CVD), chronic kidney (CKD) and
non-alcoholic fatty liver (
NAFLD) disease risk.
299 Leptin is a vital biomarker of
non-alcoholic fatty liver (
NAFLD), and its evaluation of
300 steatosis with or without mild inflammation (
non-alcoholic fatty liver),
to non-alcoholic steatohepat